RICHMOND, British Columbia, Sept. 18, 2007 (PRIME NEWSWIRE) -- BioCurex, Inc. (OTCBB:BOCX) announced today a presentation to the International Society for Oncodevelopmental Biology and Medicine (ISOBM). The presentation documents a study conducted by BioCurex in its development of a 'rapid test' for ambulatory cancer detection, based on its patented RECAF(tm) cancer marker. This study was conducted in conjunction with the Blokhin Cancer Research Centre, Moscow, Russia.
The results of this study showed that 80.4% of ovarian cancers (Stages I-III) were detected with 88% specificity. The samples included 64 normal controls, 51 serum samples from patients with ovarian cancer (25 samples at Stage I and II (b-c) and 26 samples at Stage III (b-c)). The device used in the research was similar to the common pregnancy test kit and represents a potential breakthrough of great magnitude in simplifying cancer detection.
These results show that a rapid lateral flow chromatography test based on the RECAF (tm) marker can discriminate well between cancer and normal samples. When applied to the examples of early-stage ovarian cancer, the rapid test demonstrated better performance than CA-125.
Once perfected, the rapid test may one day prove useful for a first approximation to the diagnosis of cancer at the doctor's office.
Ricardo Moro, President and CEO stated: "This presentation to the ISOBM is a validation of our ongoing R & D to develop a simple and effective approach to rapid cancer detection. The commercialization of such a rapid test will position BioCurex as a significant player in this billion dollar industry."
About The International Society of Oncodevelopmental Biology and Medicine (ISOBM):
The ISOBM originated in the early 1970's from the International Research Group for Carcinoembryonic Proteins. Since then the society has grown to cover wider aspects of research in oncodevelopmental / oncofetal biology. The society also organizes a series of Antibody Workshops. These workshops provide a practical focus on tumor markers in all types of cancer.
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.
BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF(tm) Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAF(tm) has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.